Empower your strategies with our Net Present Value Model: BioAtla Inc’s Evalstotug report and make more profitable business decisions.
Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development.
Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.

BioAtla Inc’s Evalstotug Drug Details:
Evalstotug (BA-3071) is under development for solid tumors, non-small cell lung cancer, uveal melanoma, gastroesophageal (GE) junction carcinomas, renal cell carcinoma, gastric, cervical, transitional cell carcinoma (urothelial cancer). and melanoma. It acts as checkpoint inhibitor by targeting against cytotoxic T-lymphocyte antigen 4 (CTLA-4). It is based on conditionally active biologics (CAB) that optimizes antibodies to be activated and/or inactivated at defined physiological conditions. It was under development for the treatment of colon adenocarcinoma.It was under development for small cell lung cancer, hepatocellular carcinoma and bladder cancer.
Report Coverage
GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.
Scope of Report
- Drug Name
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
- Patent law
- Known and Projected regulatory approval processes
- Cash flows
- Potential applicable patients
- Drug margins
- Company expenses
- Pricing estimates
Reasons to buy
- Obtain a better understanding of the quantitative value of Net Present Value Model: BioAtla Inc’s Evalstotug.
- Access another data source to use in the valuation of Net Present Value Model: BioAtla Inc’s Evalstotug.
- Create or support internal NPV models to improve accuracy.
- Understand a drug’s expected profit, considering revenue and cost forecasts leveraging public and proprietary data sets.







